CMA
MRNA icon

Cedar Mountain Advisors’s Moderna MRNA Stock Holding History

Cedar Mountain Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13
Closed -$383 – 1181
2025
Q4 		$383 Hold
13
– – ﹤0.01% 637
2025
Q3 		$336 Hold
13
– – ﹤0.01% 629
2025
Q2 		$359 Hold
13
– – ﹤0.01% 341
2025
Q1 		$369 Hold
13
– – ﹤0.01% 328
2024
Q4 		$541 Sell
13
-60
-82% -$2.87K ﹤0.01% 348
2024
Q3 		$4.88K Sell
73
-10
-12% -$918 ﹤0.01% 249
2024
Q2 		$9.86K Hold
83
– – ﹤0.01% 190
2024
Q1 		$8.84K Buy
83
+10
+14% +$1.01K ﹤0.01% 194
2023
Q4 		$7.26K Hold
73
– – ﹤0.01% 199
2023
Q3 		$7.54K Buy
+73
New +$8.14K ﹤0.01% 191

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cedar Mountain Advisors's MRNA Position: Q1 2026 in Review

Cedar Mountain Advisors sold out of Moderna (MRNA) in Q1 2026, closing a stake of 13 shares — an estimated $383 sold.

Cedar Mountain Advisors first reported a position in MRNA in Q3 2023 and held it in 10 quarters. The position peaked at $9.86K in Q2 2024. 725 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Cedar Mountain Advisors reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
  • Cedar Mountain Advisors sold 13 Moderna shares in Q1 2026, an estimated $383.
  • Cedar Mountain Advisors first reported a position in Moderna in Q3 2023 and held it in 10 quarters.
  • Cedar Mountain Advisors's Moderna position peaked at $9.86K in Q2 2024.
  • 725 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Cedar Mountain Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.